These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 31419399)

  • 21. Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer.
    Souza MCO; Marques MP; Duarte G; Lanchote VL
    J Pharm Biomed Anal; 2019 Feb; 164():268-275. PubMed ID: 30399533
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Novel Method for Preventing Non-specific Binding in Equilibrium Dialysis Assays Using Solutol® as an Additive.
    Srivastava A; Pike A; Williamson B; Fenner K
    J Pharm Sci; 2021 Mar; 110(3):1412-1417. PubMed ID: 33248055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of unbound fraction of pazopanib in vitro and in cancer patients reveals albumin as the main binding site.
    Imbs DC; Paludetto MN; Négrier S; Powell H; Lafont T; White-Koning M; Chatelut E; Thomas F
    Invest New Drugs; 2016 Feb; 34(1):41-8. PubMed ID: 26572909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein binding in antiretroviral therapies.
    Boffito M; Back DJ; Blaschke TF; Rowland M; Bertz RJ; Gerber JG; Miller V
    AIDS Res Hum Retroviruses; 2003 Sep; 19(9):825-35. PubMed ID: 14585213
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High performance affinity chromatography (HPAC) as a high-throughput screening tool in drug discovery to study drug-plasma protein interactions.
    Vuignier K; Guillarme D; Veuthey JL; Carrupt PA; Schappler J
    J Pharm Biomed Anal; 2013 Feb; 74():205-12. PubMed ID: 23245252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The binding of amsacrine to human plasma proteins.
    Paxton JW; Jurlina JL; Foote SE
    J Pharm Pharmacol; 1986 Jun; 38(6):432-8. PubMed ID: 2873219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Application of Cassette Ultracentrifugation Using Non-labeled Compounds and Liquid Chromatography-Tandem Mass Spectrometry Analysis for High-Throughput Protein Binding Determination.
    Kieltyka K; McAuliffe B; Cianci C; Drexler DM; Shou W; Zhang J
    J Pharm Sci; 2016 Mar; 105(3):1036-42. PubMed ID: 26886323
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pH dependency of the binding of drugs to plasma proteins in man.
    Hinderling PH; Hartmann D
    Ther Drug Monit; 2005 Feb; 27(1):71-85. PubMed ID: 15665750
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of pH on plasma protein binding in equilibrium dialysis.
    Kochansky CJ; McMasters DR; Lu P; Koeplinger KA; Kerr HH; Shou M; Korzekwa KR
    Mol Pharm; 2008; 5(3):438-48. PubMed ID: 18345638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protein-binding characteristics of voriconazole determined by high-throughput equilibrium dialysis.
    Vanstraelen K; Wauters J; De Loor H; Vercammen I; Annaert P; Lagrou K; Spriet I
    J Pharm Sci; 2014 Aug; 103(8):2565-70. PubMed ID: 24961809
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Commonly Used and New Methods to Determine Small Molecule Non-Specific Binding to Human Liver Microsomes.
    Wang T; Whitcher-Johnstone A; Scaringella YS; Keith-Luzzi M; Shao J; Taub ME; Chan TS
    J Pharm Sci; 2024 Jul; 113(7):1987-1995. PubMed ID: 38615815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of a Competitive Equilibrium Dialysis Approach for Assessing the Impact of Protein Binding on Clearance Predictions.
    Jones RS; Chang JH; Flores M; Brecht E
    J Pharm Sci; 2021 Jan; 110(1):536-542. PubMed ID: 32941852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Highly sensitive method for the determination of tamsulosin hydrochloride in human plasma dialysate, plasma and urine by high-performance liquid chromatography-electrospray tandem mass spectrometry.
    Matsushima H; Takanuki KI; Kamimura H; Watanabe T; Higuchi S
    J Chromatogr B Biomed Sci Appl; 1997 Aug; 695(2):317-27. PubMed ID: 9300868
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The use of pseudo-equilibrium constant affords improved QSAR models of human plasma protein binding.
    Zhu XW; Sedykh A; Zhu H; Liu SS; Tropsha A
    Pharm Res; 2013 Jul; 30(7):1790-8. PubMed ID: 23568522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients.
    Li J; Brahmer J; Messersmith W; Hidalgo M; Baker SD
    Invest New Drugs; 2006 Jul; 24(4):291-7. PubMed ID: 16502356
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A mass balance approach for calculation of recovery and binding enables the use of ultrafiltration as a rapid method for measurement of plasma protein binding for even highly lipophilic compounds.
    Wang C; Williams NS
    J Pharm Biomed Anal; 2013 Mar; 75():112-7. PubMed ID: 23312388
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Automation of plasma protein binding assay using rapid equilibrium dialysis device and Tecan workstation.
    Ye Z; Zetterberg C; Gao H
    J Pharm Biomed Anal; 2017 Jun; 140():210-214. PubMed ID: 28365514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro plasma protein binding determination of flunarizine using equilibrium dialysis and liquid chromatography-tandem mass spectrometry.
    Lin ZJ; Musiano D; Abbot A; Shum L
    J Pharm Biomed Anal; 2005 Apr; 37(4):757-62. PubMed ID: 15797798
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Measuring Unbound Versus Total Piperacillin Concentrations in Plasma of Critically Ill Patients: Methodological Issues and Relevance.
    Colman S; Stove V; De Waele JJ; Verstraete AG
    Ther Drug Monit; 2019 Jun; 41(3):325-330. PubMed ID: 30633089
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of in vitro drug interactions with karenitecin, a novel, highly lipophilic camptothecin derivative in phase II clinical development.
    Smith JA; Newman RA; Hausheer FH; Madden T
    J Clin Pharmacol; 2003 Sep; 43(9):1008-14. PubMed ID: 12971034
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.